The Move to Bundled Payments Will Be Paradigm-Changing

Article

As with any legislation, there are both positive and negative aspects. Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease.

Bruce Minsky, MD

It is difficult to comment on the full impact of the Affordable Care Act (ACA), since it is complex and how each provision will impact each component of health care is still not fully understood. As with any legislation, there are both positive and negative aspects.

Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease. This will refocus the question in multidisciplinary tumor boards from “what is the ideal way to stage, treat, and manage the patient” to “what is the ideal way to stage, treat, and manage the patient within the reimbursement envelope for their disease.”  The ultimate impact of these 7 paradigm-changing words remains to be determined.

More on the Supreme Court Decision

Derek Raghavan
Bruce Minsky
Nora Janjan
Michael Glod
James B. Yu
Lawrence Wagman

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content